Document Detail


Hand-foot syndrome and seborrheic dermatitis-like eruption induced by erlotinib.
MedLine Citation:
PMID:  19951638     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor that is responsible for several cutaneous side effects. We report a case of hand-foot syndrome associated with a papulo-pustular and seborrheic dermatitis-like eruption of the face in a 61-year-old patient treated with erlotinib for lung cancer.
Authors:
Sophia Benomar; Saber Boutayeb; Yassir Afifi; Syrine Hamada; Jamila Bouhllab; Badreddine Hassam; Hassan Errihanni
Related Documents :
22307178 - Standardization of flow cytometry in myelodysplastic syndromes: a report from an intern...
6232098 - The baboon syndrome: systemically-induced allergic contact dermatitis.
20948068 - Glucagonoma syndrome.
6325068 - Migraine, tolosa-hunt syndrome and pleocytosis. correlation or coincidence?
16204418 - A school-based application of modified habit reversal for tourette syndrome via a trans...
12665418 - Novel therapies in the treatment of irritable bowel syndrome.
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2009-11-15
Journal Detail:
Title:  Dermatology online journal     Volume:  15     ISSN:  1087-2108     ISO Abbreviation:  Dermatol. Online J.     Publication Date:  2009  
Date Detail:
Created Date:  2009-12-02     Completed Date:  2010-02-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9610776     Medline TA:  Dermatol Online J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2     Citation Subset:  IM    
Affiliation:
Department of dermatology, Ibn Sina Hospital, Mohamed V University of Rabat, Morocco. sophiabenomar@yahoo.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Carcinoma, Non-Small-Cell Lung / drug therapy,  pathology,  surgery
Chemotherapy, Adjuvant
Dermatitis, Seborrheic / chemically induced*,  physiopathology
Disease Progression
Drug Eruptions / etiology*,  physiopathology
Facial Dermatoses / chemically induced,  physiopathology
Follow-Up Studies
Hand Dermatoses / chemically induced,  physiopathology
Humans
Lung Neoplasms / drug therapy,  pathology,  surgery
Male
Middle Aged
Protein Kinase Inhibitors / adverse effects*,  therapeutic use
Quinazolines / adverse effects*,  therapeutic use
Risk Assessment
Syndrome
Chemical
Reg. No./Substance:
0/Protein Kinase Inhibitors; 0/Quinazolines; 0/erlotinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Melanoma costs: A dynamic model comparing estimated overall costs of various clinical stages.
Next Document:  Linear IgA bullous dermatosis following influenza vaccination.